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ABSTRACT Structural and biochemical characterization of protein kinases that confer oncogene addiction and harbor a large
number of disease-associated mutations, including RET and MET kinases, have provided insights into molecular mechanisms
associated with the protein kinase activation in human cancer. In this article, structural modeling, molecular dynamics, and free
energy simulations of a structurally conserved mutational hotspot, shared by M918T in RET and M1250T in MET kinases, are
undertaken to quantify the molecular mechanism of activation and the functional role of cancer mutations in altering protein
kinase structure, dynamics, and stability. The mechanistic basis of the activating RET and MET cancer mutations may be driven
by an appreciable free energy destabilization of the inactive kinase state in the mutational forms. According to our results, the
locally enhanced mobility of the cancer mutants and a higher conformational entropy are counterbalanced by a larger enthalpy
loss and result in the decreased thermodynamic stability. The computed protein stability differences between the wild-type and
cancer kinase mutants are consistent with circular dichroism spectroscopy and differential scanning calorimetry experiments.
These results support the molecular mechanism of activation, which causes a detrimental imbalance in the dynamic equilibrium
shifted toward the active form of the enzyme. Furthermore, computer simulations of the inhibitor binding with the oncogenic and
drug-resistant RET mutations have also provided a plausible molecular rationale for the observed differences in the inhibition
proﬁles, which is consistent with the experimental data. Finally, structural mapping of RET and MET cancer mutations and
the computed protein stability changes suggest a similar mechanism of activation, whereby the cancer mutations which display
the higher oncogenic activity tend to have the greatest destabilization effect on the inactive kinase structure.INTRODUCTION
A central goal of cancer research involves the discovery and
functional characterization of the mutated genes that drive
tumorigenesis (1,2). The Cancer Genome Atlas and related
DNA sequencing initiatives have motivated sequencing
studies of tumors and analysis of the genomic basis of tumor-
igenesis (3–8). The most common protein families impli-
cated in cancer are protein kinases, which are signaling
switches regulating the activity of their substrates by adding
phosphate groups to them, and there are >500 encoded in the
human genome (9–13). A landmark for understanding the
molecular basis of kinase function was the elucidation of
the crystal structure of protein kinase A (14,15). Since this
discovery, the crystal structures of nearly 70 different protein
kinases have been determined. Although the kinase catalytic
domain is highly conserved, protein kinase crystal structures
have revealed considerable structural differences between
the closely related active and highly specific inactive forms
of kinases (16–18). The dynamic interconversion between
distinct inactive and active protein states is a structural hall-
mark of the kinase domain, which is critical for its normal
function.
Cancer genome resequencing efforts have illuminated the
role of kinase addiction in a variety of human cancers and
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ing to their involvement in tumorigenesis (19–22). The
dominant oncogenes that confer the oncogene addiction
effect include ABL, epidermal growth factor receptor
(EGFR), VEGFR, BRAF, MET, FGFR3, ALK, RET, and
Aurora kinases (23). A comprehensive computational anal-
ysis of the distribution of nonsynonymous coding SNP and
disease-causing nonsynonymous coding SNPs within the
protein kinase gene family has shown that somatic mutations
occurring at structurally conserved kinase positions may be
statistically enriched in cancers and form mutational hotspots
that promote the tumorigenic activity of multiple protein
kinases (24–26). Recent advances in understanding genomic
and molecular signatures of cancer-causing mutations in
protein kinases have facilitated molecular studies of the
mutation-dependent activation process and have identified
somatic mutations linked to nonsmall cell lung carcinoma
within the EGFR tyrosine kinase gene (27–30). Structural
determinations of the EGFR (31–34) and ABL cancer
mutants (35,36) in complexes with various cancer drugs
have provided a molecular rationale of the kinase activation
mechanism, revealing structural divergence of the kinases in
response to activating mutations with different degrees of
sensitivity. Computational studies have begun to investigate
a molecular basis of protein kinase function and the struc-
tural effects of activating mutations, which may ultimately
doi: 10.1016/j.bpj.2008.10.041
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the scope of drug resistance mutations (37–48).
According to the KinMutbase (49,50), there are >35
unique missense MET mutations and 127 missense RET
kinase mutations. A large number of inactivating and acti-
vating mutations in the human RET tyrosine kinase domain
can cause different disorders, including Hirschprung disease
and the thyroid gland cancers (51,52). Molecular mecha-
nisms of RET activation in endocrine tumors are largely
associated with the transforming ability of specific RET
mutations (53–56). Most notably, it was discovered that
>95% of multiple endocrine neoplasia type 2 (MEN 2B)
cancers arise from M918T mutation, which can lead to
a unique pattern of RET tyrosine phosphorylation and down-
stream signaling. Moreover, functional and thermodynamic
analysis have demonstrated that the M918T mutation
can cause a local conformational change in the RET
kinase that partially releases autoinhibition, resulting in the
decreased thermal stability and the increased structural flex-
ibility of the RET mutant (54). The experimental data have
shown that structurally conserved mutants M918T in RET
(53,54) and M1250T in MET kinases (57–61) are associated
with the mechanism of oncogenic activation and display the
highest transforming potential, leading to uncontrolled cell
proliferation and tumorigenesis.
The biochemical and structural analysis of the wild-type
(WT) RET and M918T mutant have recently identified
distinct, yet complementary effects of cancer mutations on
the RET kinase function, including the increasing kinase
activity, a partial release of the kinase autoinhibition, and
ligand-independent phosphorylation of RET receptors (54).
Structural and biochemical characterization of the human
WT RET kinase dimer has been reported in both nonphos-
phorylated and phosphorylated forms (62). These crystal
structures adopt the same active kinase conformation, inde-
pendent of phosphorylation status, which only modestly
affected the level of its catalytic activity (62). Importantly,
in the absence of activation, RET kinase monomers may
also adopt a closed, autoinhibited inactive conformation, in
which the A-loop blocks access to the substrate binding
pocket (54). There are other relevant examples of tyrosine
kinases (EGFR, ACK1) with active conformations in their
nonphosphorylated forms, which may also have a structurally
different inactive conformational state (63). Of particular
importance is the recent discovery that the cancer drug Sor-
afenib can act not only as a highly potent inhibitor of BRAF
(60), but also inhibit the inactive form of the WT RET kinase
and the gatekeeper RET mutations (64). The recently solved
crystal structures of the autoinhibited form for the WT MET
kinase (65) have suggested that activating cancer mutations
may act through weakening the interactions, which stabilize
the inactive state of the kinase, but may have a negligible
effect on stabilization of the active form.
Some tyrosine kinase inhibitors, including the pyrazolo-
pyrimidines PP1 and PP2 and the 4-anilinoquinazolineZD6474 can exhibit a strong activity toward the RET kinase
and the oncogenic RET kinase mutants, and thereby may be
used to treat specifically RET-associated cancers (66–69). In
particular, ZD6474, a low molecular weight tyrosine kinase
inhibitor, blocks the enzymatic activity of RET kinase and
various RET cancer mutants, including M918T, at the inhib-
itory concentration of 100 nM, and results in the efficient
inhibition of their tumorigenic potential (68,67). Moreover,
most of the RET mutants, including M918T, E768D,
L790F, Y791F, S891A, and A883F, have shown a sensitivity
profile to ZD6474 which is very similar to that of WT RET.
In contrast, mutations substituting gate-keeper V804 either
to leucine or to methionine (V804L and V804M) can render
the RET kinase which is resistant to ZD6474 with only
a modest inhibition effect observed at 5.0 mM (67).
However, substitution of V804 with a smaller glycine
residue results in the RET kinase, which is even more
susceptible to inhibition (IC50 ¼ 20 nM) than the WT
RET kinase (IC50 ¼ 100 nM) (67). The crystal structures
of RET kinase complexes bound to two inhibitors, the
pyrazolopyrimidine PP1 and the clinically important
4-anilinoquinazoline ZD6474, have unveiled a similar binding
mode of these inhibitors, suggesting a molecular rationale for
the drug resistance against specific RET mutants (62).
In this study, molecular dynamics (MD) simulations and
free energy stability analysis of the structurally conserved
mutations in the RET and MET kinases are undertaken
from a biophysical perspective to investigate the role of these
mutations in the molecular mechanism of activation. More-
over, we have also performed MD simulations and docking
and binding free energy evaluations of the inhibitor binding
with the oncogenic and drug-resistant RET mutants.
Combined with a structural mapping of the RET and MET
cancer mutations and the computed protein stability changes,
the results of this study offer a plausible common mecha-
nism, according to which activating cancer mutations may
trigger a partial destabilization of the inactive kinase, while
contributing to the enhanced stabilization of the active kinase
form.
METHODS
Structural modeling
Structural modeling of M918T RET and M1250T MET mutations has been
carried out using MODELLER (70,71) with a subsequent refinement of side
chains by the SCRWL3 program (72). The initial M918T RET model in the
active state was obtained using crystal structures of nonphosphorylated
(Protein Data Base (PDB) code 2IVS) WT RET kinase in the active state.
The initial structural models of the WT RET and M918T RET mutant in
the inactive, autoinhibited form were constructed using the crystal structures
of the closest homologous kinase, FGFR1, in the inactive state (PDB entries
1FGI, 1FGK) as structural templates. The resulting models were compared
and found to be essentially identical to a validated theoretical model of inac-
tive human RET (PDB code 1XPD). Structural model of the M1250T MET
kinase mutant in the inactive state was obtained based on the crystal struc-
ture of the unphosporylated, autoinhibited form of the WT MET kinase
(PDB code 2G15); the inactive WT FLT3 (PDB code 1RJB), and theBiophysical Journal 96(3) 858–874
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built in MODELLER with a flexible sphere of 5 A˚ around each mutated
residue. In the final protocol, we gradually increased the radius of this sphere
in 5 A˚ steps until the radius reached the 25 A˚ value (i.e., all residues falling
within this range were treated as flexible). A hybrid protocol involving 5000
steps of a conjugate-gradient minimization, followed by MD with simulated
annealing (SA) refinement, was repeated 20 times to generate 100 initial
models for each cancer mutant in this study. In the optimization stage, we
initially used a conjugate-gradient minimization to remove unfavorable
contacts and to optimize geometry. MD simulations were then run at
increasing temperature values from 150 K to 1500 K, followed by simulated
annealing and sampling at temperatures of 1500 K, 1000 K, 800 K, 600 K,
500 K, 400 K, 320 K, and 300 K, respectively. The models were generated
using 20 iterations of the MD/SA procedure and the predicted structural
model was chosen out of the 100 models as scored by the MODELLER
default scoring function. These models were then relaxed using 1-ns MD
simulations with NAMD 2.6 software package and the CHARMM22 force
field (73) to ensure local refinement of the environment surrounding the
mutant residue (all residues within 5 A˚ distance), while keeping the rest
of the protein rigid.
Molecular dynamics simulations
All MD simulations of the RET and MET kinase forms were done for 20 ns
with the explicit solvent using NAMD 2.6 with the CHARMM22 force field
(73). The VMD program was used for the preparation and analysis phases of
simulations (74,75). The psfgen utility in the VMD software was employed
to generate a protein structure file for MD simulations with the CHARMM
27 force field. The kinase structures were solvated in a large box of water
with 15 A˚ buffering distance. Assuming normal charge states of ionizable
groups corresponding to pH 7, sodium Naþ and chloride Cl counterions
at physiological concentration of 0.15 mol/L were added to achieve charge
neutrality and to mimic a realistic biological environment more closely. All
Naþ and Cl ions were placed >8 A˚ away from any protein atoms and from
each other. The structure of RET kinase is unresolved for flexible residues
828–843, which were modeled and incorporated into the final structure using
MODELLER (70,71) with an additional refinement of side chains by the
SCRWL3 program (72) and minimization. During simulations with the inac-
tive (PDB entry 1XPD) and active forms of WT RET (PDB entry 2IVS), the
total number of simulated atoms in the system is 59,310 including 4908
protein atoms; 18,117 water molecules, and 22 sodium Naþ and 27 chloride
Cl counterions. In simulations with the M918T RET mutant, the total
number of simulated atoms in the system is the same (59,310), including
4905 protein atoms (because of the effect of the mutated residue); 18,118
water molecules; and 22 sodium Naþ and 27 chloride Cl counterions,
respectively. During MD simulations with the WT MET and M1250T
MET mutant (PDB entry 2G15), the total number of simulated atoms in
the system is also the same (59,783), including 4826 protein atoms for the
MET WT (4823 for the MET M1250T mutant); 18,302 water molecules
for the MET WT (18,303 for the MET M1250T mutant); and 51 sodium
Naþ and 25 chloride Cl counterions.
The system was subjected to initial minimization for 10,000 steps keeping
protein atoms fixed (minimization of water molecules) followed by the
another 10,000 steps of minimization keeping only the protein backbone
fixed so as to allow protein side chains to relax. This was followed by
10,000 steps of minimization to allow the entire system to relax freely.
The equilibration and simulation protocol was carried out in steps by grad-
ually increasing the system temperature in steps of 20 K starting from 10 K
until 310 K, and at each step 20 ps equilibration was run keeping a restraint
of 10 Kcal mol1 A˚2 on protein a-carbons. Thereafter the system was
equilibrated for 300 ps at 310 K (NVT) and then for a further 300 ps at
310 K using the Langevin piston (NPT) to maintain the pressure. At the final
stage of equilibration, the restraints were completely removed and the entire
system was equilibrated for an additional 2-ns time period. After the equil-
ibration phase had been completed, MD simulations in NPT ensemble were
run using the equilibrated structure for 20 ns of the production period,Biophysical Journal 96(3) 858–874keeping the temperature at 310 K and pressure at 1 bar using the Langevin
piston coupling algorithm. The integration time step of the simulations was
set to 2.0 fs, the SHAKE algorithm was used to constrain the lengths of all
chemical bonds involving hydrogen atoms at their equilibrium values, and
the water geometry was restrained as rigid by using the SETTLE algorithm.
Nonbonded van der Waals interactions were treated by using a switching
function at 10 A˚ and reaching zero at 12 A˚ distance. The particle-mesh
Ewald algorithm (76), as implemented in NAMD, was used to compute
long-range electrostatic forces.
Molecular docking simulations
We have modeled binding of ZD6474 inhibitor with the WT RET, M918T
RET, V804M, and V804G RET mutants using 1000 snapshots from the MD
trajectory of the ZD6474 inhibitor bound with the WT RET, followed by 1),
modeling these mutations into each of the 1000 snapshots and subsequent
10,000 steps of energy minimization; and 2), inhibitor docking with 1000
conformations of the WT and RET mutants. Docking simulations are per-
formed using a combination of the evolutionary search algorithm and the
knowledge-based energy model, which have been extensively documented
in our earlier studies (77). In brief, the inhibitor conformations and orienta-
tions are sampled in a parallelepiped that encompasses the binding site
obtained from the crystallographic structure of the RET kinase complexes
with a large 20.0 A˚ cushion added to every side of this box surrounding
the interface. The protein structure is held fixed in its minimized and equil-
ibrated conformation, while rigid body degrees of freedom and the peptide
rotatable angles are treated as independent variables. The initial inhibitor
conformations are generated by randomizing the encoded vector, where
the center of mass of the ligand is restricted to the rectangular parallelepiped
that encompasses the RET crystal structures. The three rigid-body rotational
degrees of freedom as well as the torsional angles for all rotatable bonds are
uniformly initialized between 0 and 360.
Free energy simulations
Free energy calculations of the protein kinase stabilities and binding free
energy computations are done using the molecular mechanics AMBER force
field (78) and the solvation energy term based on the continuum generalized
Born and solvent-accessible surface area (GB/SA) solvation model (79,80).
The length of MD simulations and the size of the investigated molecules are
usually hampered by the necessity of including thousands of explicit solvent
molecules. The continuum dielectric methods evaluate only the solute elec-
trostatics and consequently reduce the number of interactions with respect to
explicit solvent methods. These methods have proven to be reliable and able
to provide crucial information for various biomolecules (79,80). The gener-
alized Born (GB) theory is an approximation of the Poisson equation for
continuum electrostatic solvation energy. It involves accurate evaluation
of Born radii, which characterize the average spherical distances of each
atom to the solvent boundary. Consequently, the GB energy expression
can reliably reproduce the Poisson energy at a significantly lower computa-
tional cost (79,80). The details of the MM-GBSA model typically used in
free energy simulations of biological systems have been extensively docu-
mented in our earlier studies (46,47,81–83). Here, we outline the major
components of the computational model that are relevant in the context of
this study. The total free energy is given as
Gmolecule ¼ Ggbtot þ Egas  TSsolute; (1)
where Gsolvation is the solvation free energy, and Egas is the molecular
mechanical energy of the molecule summing up the electrostatic Eele inter-
actions, van der Waals contributions Evdw, and the internal strain energy Eint.
TSsolute is the sum of TStrans, TSrot, and TSvib, which are the translational,
rotational, and vibrational entropy contributions, respectively. The vibra-
tional entropy term is determined using the NMODE module of the normal
mode analysis involving calculation and diagonalization of a mass-weighted
second derivative matrix.
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mutants were calculated and averaged for 1000 snapshots, selected at
20-ps intervals along the 20-ns MD trajectories for each of these systems.
It is worth stressing that because normal mode analysis scales quadratically
with the size of the structure, these computations continue to be rather
computationally intensive and are frequently omitted in calculations of large
biological systems. In our study, we have systematically applied normal
mode analysis for all studied RET and MET kinases to determine the entropy
contribution to the free energy and accurately assess differences in the
protein stability between WT and mutant kinases.
The electrostatic contribution to the solvation free energy Ggbele involves
using the GB equation to estimate the electrostatic contributions to the solva-
tion free energy and typically leads to a small error compared to the Poisson-
Boltzmann approach (79,80). The nonpolar contribution to the solvation free
energy, Ggbnp, was determined using the linear combinations-of-pairwise
overlaps method where the hydrophobic contribution to the solvation free
energy is determined by the solvent-accessible-surface-area (SASA) depen-
dent term. The total solvation free energy Ggbtot is the sum of the nonpolar
Ggbnp and polar Ggbele contributions. The Geletot is the total electrostatic
energy and is the sum of the electrostatic solvation free energy and molecular
mechanics electrostatic energy.
Using the MM-GBSA module in AMBER 8.0, we have evaluated protein
stability differences between 1), WT RET kinase and the M918T mutant and
2), WT MET and M1250T MET in both inactive and active states of the
enzyme. A practical implementation of this approach involved computation
of the energy contributions for each of the selected 1000 snapshots at 20-ps
intervals along the 20-ns MD trajectories for each of these systems, followed
by averaging to obtain the total free energy values. The trajectories obtained
from the earlier 20 ns MD runs were converted into individual PDB files in
VMD. These 1000 coordinate frames were then converted into AMBER-
compatible files using utilities from the multiscale modeling tools for
structural biology tool set (http://www.mmtsb.org/). The names of phos-
phorylated residues of MET and RET were modified to load all the required
libraries and parameters for phosphorylated residues. The AMBER parame-
ters and coordinate files were then generated using the Leap module in
AMBER and subsequently used in the MM-GBSA calculation.
The binding free energy of the inhibitor-kinase complexes is given by the
expression
Gbind ¼ Gcomplex  Gprotein  Gligand: (2)
Binding free energy evaluations can be performed using either separate
trajectories of the complex, protein, and ligand (separate trajectory protocol)
or from a trajectory of the complex (single trajectory protocol) (84). We have
used a single trajectory protocol based on 1000 snapshots of the inhibitor
complexes with the WT RET and RET mutants. This approach is less
computationally intensive and may also be less sensitive because of cancel-
lation of the intramolecular energies, caused by neglecting the effects of
structural adaptation during binding.
Protein stability calculations
To quantify the destabilization effect of a number of known RET and MET
cancer mutations in the inactive, autoinhibited kinase form, we computed the
protein stability change upon these mutations using three different
approaches with the increasing level of complexity: 1), Cologne University
Protein Stability Analysis Tool (CUPSAT) approach for the prediction and
analysis of protein stability changes upon point mutations (85,86); 2),
FOLDx approach, which allows the calculation of the free energy of a macro-
molecule based on its high-resolution three-dimensional structure (87); and
3), MM-GBSA free energy calculations (79,80). In the CUPSAT approach,
coarse-grained atom potentials and torsion angle potentials are used to
predict protein stability upon point mutations (85). FOLDx analysis of
protein stability is based on the empirical force field, which was developed
for the rapid evaluation of the effect of mutations on the stability, folding,
and dynamics of proteins and nucleic acids (88). The free energy of foldingis evaluated in this approach from the difference in Gibbs free energy
between the crystal structure of the protein and a hypothetical unfolded
reference state of which no structural details are known.
The protein stability changes for a spectrum of studied RET and MET
mutants are also evaluated using a single trajectory MM-GBSA approach,
in which 1000 snapshots were extracted from 20-ns MD trajectories of the
WT RET and WT MET in the autoinhibited, inactive state. The RET and
MET mutations were modeled into each of the 1000 snapshots of the WT
trajectories, followed by a subsequent 10,000 steps of energy minimization.
The protein stability differences are approximated based on the total free
energy difference between the WT and mutant kinase conformations:
DGtotal ¼ DEgas þ DGgbtot  TDSsolute: (3)
RESULTS AND DISCUSSION
Evolutionary and structurally conserved M918 RET (Fig. 1,
A and B) and M1250 MET (Fig. 1, C and D) residues are
localized in the substrate binding C-lobe of the kinase
core. Somatic mutations occurring at this structurally
conserved kinase position are implicated in the tumorigenic
activity of multiple protein kinases, including M918T RET
and M1250T MET. Moreover, this mutational hotspot is
also shared in ALK1 (M-R), MET (M-T), RET (M-T), and
TGFbR2 (M-V). Three of the four mutations are transitions
from methionine to either arginine or threonine, indicating
that these mutations may disrupt the hydrophobic binding
pocket by introducing polar amino acids. This methionine
is highly conserved and specific for receptor tyrosine
kinases, while in cytosolic tyrosine kinases, including
SRC, ABL and LCK, this residue is converted to threonine.
M918T in RET and M1250T in MET are situated within the
WMxxEx motif, also known as the Pþ1 loop (Fig. 1). This
loop is a small motif, which is immediately C-terminal of the
A-loop and plays an important role in recognizing the resi-
dues flanking the target tyrosine in the substrate. Our study
is designed to quantify the role of this mutational hotspot
in altering structure and dynamics of RET and MET kinases
and assess their effect on the activation mechanism.
Analysis of the cancer mutation effects in the
inactive RET kinase: molecular dynamics and
protein stability
We have performed 20-ns MD simulations for the WT RET
and tumorigenic M918T RET mutant (Fig. 1, A and B),
which were independently launched from both inactive and
active kinase structures. Structural and energetic analysis
of these trajectories allows us to investigate the effect of
the cancer mutation on protein structure and dynamics at
atomic details. To provide a computational framework for
a comparative structural and mechanistic analysis of WT
RET and M918T RET, it is desirable to have crystal struc-
tures of these proteins in both active and inactive forms.
While the existing crystal structures of both phosphorylated
and nonphosphorylated RET have the same active conforma-
tion (62), it has been established that in the absence ofBiophysical Journal 96(3) 858–874
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of the wild-type RET kinase in the active
form (PDB entry 2IVS). (B) A closeup
of structural environment near M918T
mutation in the RET kinase. (C) The
crystal structure of the wild-type MET
kinase in the inactive, autoinhibited
form (PDB entry 2G15). (D) A closeup
of structural environment near M1250T
mutation in the MET kinase.activation, RET kinase monomers may adopt a closed,
autoinhibited inactive conformation (54). Consequently, to
simulate dynamics of the RET kinase in the inactive, autoin-
hibited form, we have built a homology model of the inactive
RET using the crystal structures of the closest homologous
kinase FGFR1 in the inactive form (PDB entries 1FGI and
1FGK) as structural templates. It is worth noting that the
generated refined RET model is very similar to the previ-
ously validated and PDB-deposited modeled structure of
the inactive human RET kinase (PDB code 1XPD).
Examination of the MD trajectories in the inactive state
highlights some important similarities and differences in
the dynamical behavior of the WT RET and M918T RET
mutant. Indeed, while WT RET tends to rapidly reach
a steady equilibrium, the root mean-square deviation
(RMSD) fluctuations for the M918T mutant were noticeably
larger, reaching an equilibrium plateau after a considerably
longer simulation period (Fig. 2 A). The equilibrium struc-
tures of the WT RET fluctuated within ~2.0 A˚ from the
crystal structure, and 3.0 A˚ for the M918T RET mutant
(Fig. 2 A). To assess the effect of M918T RET mutation
on the protein kinase structure and dynamics, we have also
computed the root mean-square fluctuation (RMSF) values,
i.e., the average residue fluctuations of the backbone resi-
dues. In agreement with the structural factors, the regions
of larger thermal fluctuations and the increased protein flex-
ibility include segments of N-terminal, C-helix, and A-loopBiophysical Journal 96(3) 858–874(Fig. 2 B). MD simulations in the inactive, autoinhibited
RET conformation have also shown that larger fluctuations
in the M918T mutant coexist with the globally similar
dynamic profiles of the WT RET and M918T mutant.
Furthermore, MD simulations have pointed to the locally
increased conformational mobility of the mutant structure
near the mutational site at the Pþ1 pocket and A-loop
(Fig. 2 B).
The residues comprising the Pþ1 substrate binding pocket
in RET are highly conserved and include I913, P914, V915,
M918, S922, L923, and Y928 (Fig. 1, A and B). In the auto-
inhibited form of WT RET, M918 interacts with residues in
the activation (I913) and Pþ1 (P914) loops and with neigh-
boring residues S922, L923, and Y928, which in turn interact
with Pþ1 and catalytic loop residues, forming a closed, auto-
inhibited structure. In the course of simulations, the hydro-
phobic contacts formed by the side chain of M918 in the
Pþ1 pocket with the I913, V915, S922, L923, and Y928
residues are maintained, indicating their importance in
controlling the inactive conformation of the WT RET kinase.
Mutation to a smaller hydrophilic threonine may elicit
a protein response with the altered shape of the Pþ1 site
and weakened packing interactions, particularly a loss of
favorable intramolecular contacts formed by T918 with the
I913 and Y928 residues (Fig. 3). Nevertheless, the mutated
T918 continues to interact with V915, S922, and further
strengthens interactions with L923 (Fig. 3). Structural effects
Modeling Kinase Cancer Mutation Effects 863FIGURE 2 The RMSD values for Ca atoms from 20-ns simulations with the inactive RET kinase (A) and the active RET kinase. (C) The RMSF values of the
RET kinase residues (using original numbering in the PDB entries 1XPD and 2IVS) from 20-ns MD simulations with the inactive RET kinase (B) and the
active RET kinase (D). For all panels, time evolution of the WT RET is shown in blue; time evolution of the M918T RET mutant is shown in red.of M918T are manifested through the enhanced local flexi-
bility, which is reflected in the increased distances with the
Y928 residue and a concomitant enlargement of the Pþ1
binding site (Fig. 4). At the same time, mutated T918 residue
maintains favorable contacts with V915 and improves inter-
actions with L923, which collectively amount to a subtly re-
shaped Pþ1 pocket. These results suggest that a locally more
mobile conformation of the T918 RET mutant as compared
to the WT RET, along with a subtly reshaped Pþ1 recogni-
tion pocket, may be functionally linked with the experimen-
tally observed subversion in substrate specificity (89,90).
Upon activation of WT RET interactions between M918
and some of these residues (S922) are reduced in strength,
but are maintained with the V915, L923, and Y928 residues.
The mutated T918 residue in the inactive state retains some
of the normal interactions of M918 in autoinhibited WT
RET, but can also acquire some of the interactions present
in the active WT RET.
Using MM-GBSA analysis of the MD trajectories for the
WT RET and M918T RET mutant, we have evaluated
protein stability changes upon mutation (Tables 1 and 2).
This analysis demonstrates that the higher conformational
mobility and a greater entropy component of the free energy
in the M918T mutant is largely offset by the loss in theenthalpy contribution. As a result, the increased protein flex-
ibility in the inactive state of M918T RET can lead to the
decreased protein stability of the mutant kinase relative to
the WT RET (Tables 1 and 2). The enthalpy loss in the
M918T RET mutant is determined by the less favorable
molecular mechanical energy of the molecule Egas, which
cannot be offset by a more favorable total solvation free
energy Ggbtot (Tables 1 and 2). In fact, the energy loss is de-
tected for all components of the molecular mechanical
energy Egas, including Eele, Evdw, and Eint contributions
(Table 1). These results are consistent with the functional
and thermodynamic analysis, which compared the overall
thermal stability and structural flexibility of the autoinhibited
forms of the WT RET and M918T mutant (54). According to
these experiments, in the inactive kinase state, the M918T
RET mutant has a lower melting temperature and is more
conformationally flexible than the WT enzyme.
It is worth stressing that there are many biological systems
and numerous examples where there is no a simple inverse
relationship between decreased molecular fluctuations and
increased stability. In general, coupling between rigid and
flexible regions of a protein and correlation of various
motions may lead to both increases and decreases in thermo-
dynamic stability. There are many protein systems with bothBiophysical Journal 96(3) 858–874
864 Dixit et al.FIGURE 3 Analysis of MD simulations with the inactive RET kinase. Time evolution history of the distances between Ca atoms of the residues in the local
structural environment of the mutational site. Time evolution of the distances between Ca atoms of the M918T RET and V915 RET (A), M918T RET and S922
RET (B), M918T RET and L923 RET (C), and M918T RET and Y928 RET (D). Time evolution of the distances for the M918 WT RET is shown in blue; time
evolution of the distances for the T918 RET mutant is shown in red.high thermal stability and flexibility (91) as well as exam-
ples of proteins where enhanced thermal stability can be
achieved without increased conformational rigidity (92).
Some mutations may disrupt long-range coupled regions ofBiophysical Journal 96(3) 858–874structural communication, while other mutations may result
in local changes, depending on structural interactions near
sites of substitution. In this study, the impact of the cancer
mutation manifests in the overall loss of the RET kinaseFIGURE 4 (A) The average structure of the inactive
form of the WT RET kinase with M918 residue shown in
CPK model. (B) A closeup of structural packing near the
mutational site in the inactive WT RET kinase. (C) The
average structure of the inactive form of the M918T RET
kinase mutant with T918 residue shown in CPK model.
(D) A closeup of structural packing near the mutational
site in the inactive T918 RET kinase.
Modeling Kinase Cancer Mutation Effects 865TABLE 1 The energy components of the MM-GBSA calculations of the protein kinase stability
Kinase
RET inactive RET active MET inactive
WT M918T WT M918T WT M1250T
Eele 10074.36 (111.75) 9678.37 (103.89) 9012.11 (100.03) 9185.27 (76.77) 9056.93 (62.83) 8970.41 (81.8)
Evdw 1693.18 (20.46) 1634.10 (20.63) 1699.82 (11.17) 1706.34 (15.21) 1665.84 (12.17) 1677.04 (16.09)
Eint 3202.34 (14.10) 3184.81 (10.81) 3010.75 (18.41) 3001.72 (10.7) 3227.72 (12.56) 3223.23 (11.97)
Egas 8565.20 (108.70) 8127.66 (108.34) 7701.19 (97.6) 7889.89 (75.18) 7494.96 (66.74) 7424.22 (83.67)
Ggbub 106.80 (2.49) 117.46 (3.36) 96.97 (1.57) 95.60 (2.13) 112.69 (1.85) 113.30 (1.18)
Ggbele 4212.55 (98.71) 4617.55 (102.96) 4182.58 (92.63) 4018.33 (70.19) 3857.12 (58.72) 3898.15 (71.24)
Ggbtot 4105.75 (97.68) 4500.09 (101.82) 4085.61 (91.63) 3922.73 (69.89) 3744.43 (57.86) 3784.86 (70.32)
Geletot 14,286.92 (20.12) 14,295.92 (12.70) 13,194.69 (17.63) 13,203.61 (13.69) 12,913.95 (18.42) 1168.56 (18.92)
EgasþGgbtot 12,670.95 (19.37) 12,627.75 (23.98) 11,768.80 (21.76) 11,812.62 (20.17) 11,239.39 (18.42) 11,209.08 (20.98)
TStrans 17.14 (0.00) 17.14 (0.00) 17.08 (0.00) 17.08 (0.00) 17.12 (0.0) 17.12 (0.0)
TSrot 17.78 (0.01) 17.84 (0.01) 17.70 (0.01) 17.68 (0.01) 17.83 (0.01) 17.82 (0.01)
TSvib 3496.14 (12.84) 3524.26 (11.27) 3311.5 (10.52) 3294.59 (11.85) 3475.16 (10.23) 3488.04 (9.63)
TStotal 3531.06 (12.85) 3559.23 (11.27) 3346.28 (10.52) 3329.36 (11.85) 3510.11 (10.24) 3522.98 (9.63)
All energies are in Kcal/mol. The contributions of the free energies are defined in Materials and Methods. The values in parentheses represent the standard
deviation values.stability in the inactive state, caused by local structural
changes, where a moderate gain in the conformational entropy
is accompanied by a larger enthalpy loss and the decreased
thermodynamic stability (Table 1).
Analysis of the cancer mutation effects in the
active RET kinase: molecular dynamics and
protein stability
MD trajectories initiated from the crystal structure of the
active RET enzyme rapidly reach equilibrium, exhibiting
small 1.0 A˚ deviations in the RMSD values for WT and
1.5–2.0 A˚ for the mutant (Fig. 2 C). Thermal fluctuations
of the WT RET and M918T RET in the active state are
largely conserved, including similar conformational flexi-
bility of the functionally important regions near the muta-
tional site, including the Pþ1 pocket and the adjacent
segment of the A-loop (Fig. 5). There are no appreciable
changes in the shape of the Pþ1 pocket in the active form
of M918T RET as compared to the WT RET (Fig. 5). As
a result, all favorable interactions formed in the Pþ1 pocket
of M918T RET are preserved and even further strengthened
TABLE 2 The differences in the protein stabilities between WT
and mutant RET and MET kinases
Kinase
RET active
GWT-GMUT
RET active
GWT-GMUT
MET inactive
GWT-GMUT
DEele 359.99 173.16 86.42
DEvdw 59.08 6.52 11.2
DEint 17.53 9.03 4.49
DEgas 437.54 188.70 70.74
DGgbub 10.66 1.37 0.61
DGgbele 405.0 164.25 41.03
DGgbtot 394.34 162.88 40.43
DEgasþDGgbtot 43.20 25.82 30.31
DTStotal 28.17 16.92 12.87
DGtotal 15.03 8.90 17.44
All energies are in Kcal/mol. The contributions of the free energy are defined
in Materials and Methods.in the active state. We have found that the M918T mutation
may further stabilize the active RET conformation, leading
to the increased thermodynamic stability (Table 1). A rather
moderate loss in the entropy TSsolute of the active M918T
RET and an unfavorable change in the total solvation energy
Ggbtot are fully compensated by considerably more favorable
intramolecular interactions reflected in the predicted Egas
values (Tables 1 and 2).
These results are fully consistent with circular dichroism
spectroscopy experiments, in which no significant variations
are seen in the secondary or tertiary structure of the M918T
RET mutant (54). Interestingly, it was also proposed that the
M918T mutation may affect the interlobe flexibility of the
kinase domain and weaken the trans-inhibitory dimer inter-
action, which may favor the active state of the enzyme (62).
Hence, the results of simulations suggest that a molecular
basis of mutations that can contribute to the activation poten-
tial of RET kinase may be manifested through increased
local mobility at functionally critical regions and reduction
in the tight interactions seen in the autoinhibited form of
WT RET.
We have also found that RET kinase may be less stable in
the active form of the enzyme than in the inactive state. Our
analysis suggests the loss of protein stability in the active
form of RET as compared to the autoinhibited inactive
form for both WT and mutant (Table 1). These results are
consistent with the experimentally observed lower melting
temperatures of the active RET form (54), which are also
seen in the thermodynamic effects of the release of autoinhi-
bition in other kinases. In addition, these data are consistent
with the earlier experimental studies (93,94), which have
discovered the decrease in the level of stabilization of the
IRK kinase, as a result of autophosphorylation and respec-
tive conformational transition to the active form of the
enzyme (93,94).
Overall, the results quantify the hypothesis that the
M918T RET mutant may be more stable in the active formBiophysical Journal 96(3) 858–874
866 Dixit et al.FIGURE 5 (A) The average structure of the ACTIVE
form of WT RET kinase with M918 residue shown in
CPK model. (B) A closeup of structural packing near the
mutational site in the ACTIVE WT RET kinase. (C) The
average structure of the ACTIVE form of M918T RET
kinase mutant with T918 residue shown in CPK model.
(D) A closeup of structural packing near the mutational
site in the ACTIVE T918 RET kinase.of the enzyme, which could provide the thermodynamic
basis for diverting the normal equilibrium toward an exces-
sively stable active kinase form for the cancer mutant. This
effect may contribute to the high oncogenic activity and
profound transforming potential of the M918T mutation.
Together, these data suggest that changes in the intramolec-
ular interactions may play a significant role in modulating
functional effects of the M918T mutation in RET kinase.
Additionally, the predicted structural effect of the M918T
mutation on protein kinase dynamics and stability is sup-
ported by isothermal titration and differential scanning calo-
rimetry experiments, which have revealed that WT RET and
M918T RET kinases have very similar melting temperatures
and consequently similarly stable structures in the active
form (54).
Molecular dynamics and protein stability analysis
of cancer mutation effects in the MET kinase
MD simulations of the MET kinase and M1250T mutant are
based on the unphosporylated, autoinhibited crystal structure
of the enzyme in the inactive form (95). These simulations
provide further insight into structural implications of a cancer
mutational hotspot on protein dynamics and activation
mechanism. Examination of the MD trajectories shows
more significant differences in flexibility between WT and
mutant, as evidenced by larger RMSD values for the
M1250T mutant reaching 2.0–2.2 A˚ as compared to 1.0 A˚
for the WT (Fig. 6 A). Moreover, larger protein fluctuations
in the M1250T mutant include regions of N-terminal, C-
helix, A-loop, and Pþ1 pocket (Fig. 6 B). The Pþ1 binding
pocket in MET is formed by the L1245, P1246, V1247,
M1250, S1254, L1255, and F1260 residues (Figs. 7 and
8). Analysis of the evolutionary and structurally conservedBiophysical Journal 96(3) 858–874Pþ1 binding pocket reveals only very minor differences
between RET and MET kinases, namely I913 RET corre-
sponds to L1245 MET and Y928 RET is converted into
F1260 MET. The local structural environment of conserved
M1250 in the MET kinase is formed by a similar network of
favorable packing interactions with neighboring V1247,
S1254, L1245, and F1260 residues. Importantly, in the
M1250T mutant a number of these favorable interactions
are weakened, most notably reflected in the increased contact
distances with the S1254 (Fig. 7 C) and smaller changes in
the hydrophobic contacts with V1247 and F1260 residues
(Fig. 7, B and D). Moreover, this mutation seems to elicit
a conformational change in the L1245 side chain that may
partially disturb the optimal arrangement between the
L1245 and V1247 residues from the A-loop and Pþ1 loop,
respectively (Fig. 8), which partly control the accessibility
of the substrate-binding pocket. MD simulations have re-
vealed that the M1250T substitution in MET may lead to
the greater local mobility near mutational site and an expan-
sion of the Pþ1 pocket as compared to the WT MET kinase
structure (Fig. 8). As a result, M1250T mutant may destabi-
lize structurally rigid, inactive MET conformation through
a partial displacement of the A-loop from the autoinhibitory
position (Fig. 8). A concomitant loosening of the interactions
between residues in the activation and Pþ1 loops can lead to
the eventual release of the inactive autoinhibitory conforma-
tion of the enzyme and the increased accessibility of the
substrate binding pocket.
Hence, we have predicted that the mechanistic basis of the
activating M1250T MET mutation may be driven by an
appreciable free energy destabilization of the inactive kinase
state in the mutational form. It appears that the higher confor-
mational mobility of M1250T in MET, as compared to the
WT MET, is largely canceled out by detrimental changes
Modeling Kinase Cancer Mutation Effects 867in the intramolecular interactions and the overall enthalpy
loss (Table 1). These results support the molecular mecha-
nism of activation, which causes a detrimental imbalance
in the dynamic equilibrium shifted toward the active form
of the enzyme. This effect may be an important contributing
factor of the adverse character and transforming properties of
the M1250T MET mutation.
It is worth noting at this point that while MD simula-
tions reveal functionally relevant conformational motions
and flexibility of the A-loop, computationally feasible
timescales of simulations are not sufficient to observe
reproducible and reversible transitions between the closed
and opened enzyme forms. Our attempts to considerably
extend the timescale based on MD simulations with the
crystal structure of the active RET kinase and the crystal
structure of the inactive MET kinase suggest that direct
simulations of such large conformational changes may be
still beyond our current capabilities and require alternative
approaches such as targeted molecular dynamics
(40,42,96).
FIGURE 6 (A) The RMSD values for Ca atoms from 20-ns MD simula-
tions with the inactive MET kinase. Time evolution of the WT is shown
in blue; time evolution of the M1250T mutant is shown in red. (B) The
RMSF values of the RET kinase residues (using original numbering in the
PDB entry 2G15) from 20-ns MD simulations with the inactive MET kinase.
Time evolution of the WT is shown in blue; time evolution of the M1250T
mutant is shown in red.Docking and binding simulations of the RET
kinase inhibitor with the cancer mutants
The recently solved crystal structures and thermodynamic
data of the WT RET (PDB entries 2IVS and 2IVT) and
RET complexes with ZD6474 (PDB entry 2IVU) (62)
have provided a basis for molecular docking and binding
free energy simulations. We have employed the results of
MD simulations performed for the WT RET and M918T
mutant, and followed with MD simulations of the RET
complex with ZD6474 to investigate molecular determinants
mediating binding and resistance of oncogenic forms of the
RET kinase with the 4-anilinoquinazoline ZD6474 inhibitor
(Fig. 9). The binding free energy analysis of the V804G and
V804M mutations was carried out using the results of MD
simulations of the WT RET, followed by introducing the
respective mutation to the 1000 representative RET confor-
mations and docking of the inhibitor to the obtained confor-
mational ensemble of RET mutants.
In agreement with the experimental data, binding simula-
tions of the RET kinase complexes have predicted the
binding mode of the ZD6474 inhibitor with the WT RET,
which is virtually identical to the crystallographic conforma-
tion (Fig. 9, A and B). The analysis of the crystal structure
and the predicted inhibitor conformation shows a virtually
identical position of the bromofluorophenyl group of
ZD6474, which occupies a hydrophobic cavity near the
back of the ATP site in the optimal proximity of V804
(Fig. 9 B). Although the inhibitor does make hydrogen bonds
with Val-804, the size of the side chain at this position is
important in controlling access to this small pocket. Indeed,
simulations with the V804G RET mutant suggest a more
tightly bound conformation of the inhibitor, which optimizes
interactions of the bromofluorophenyl inhibitor group in the
created cavity and improves the overall fit of the inhibitor in
the binding site (Fig. 9 C). In contrast, Val-804 mutations to
the larger Leu and Met residues can severely interfere with
the binding of the inhibitor and render resistance to
ZD6474. The inhibitor may compromise the favorable
extended structure, being forced to adopt an intrinsically
strained conformation to avoid direct van der Waals clashes
with the V804M residue (Fig. 9 D). These changes may only
partially improve the intermolecular inhibitor interactions
with the V804M and packing against the Lys-858 side chain,
while leading to overall dramatic loss in the binding affinity
due to combined loss of the favorable intramolecular and
intermolecular contacts (Fig. 10).
The predicted binding free energies of the ZD6474
complexes with the WT RET and mutants agree with the
biochemical data (66–69). A considerable improvement in
the binding affinity of ZD6474 with the V804G RET mutant,
as compared to the WT RET, is in full accordance with the
experimentally observed inhibition values. In a sharp
contrast, docking simulations with the conformations of
the V804M RET mutant lead to significant changes in theBiophysical Journal 96(3) 858–874
868 Dixit et al.FIGURE 7 Analysis of MD simulations with the inactive MET kinase. Time evolution of the distances between Ca atoms of the residues in the local struc-
tural environment of the mutational site. Time evolution of the distances between Ca atoms of the M1250T MET and L1245 MET (A), M1250T MET and
V1257 MET (B), M1250T MET and S1254 MET (C), and M1250T MET and F1260 MET (D). Time evolution of the distances for the M1250 WT MET is
shown in blue; time evolution of the distances for the T1250 MET mutant is shown in red.binding mode of the inhibitor, which encounters severe steric
clashes with the larger hydrophobic residue at the gate-
keeper position and abrogates efficient inhibitor binding
(Fig. 9 D). Hence, docking and binding free-energy evalua-Biophysical Journal 96(3) 858–874tions of the inhibitor binding with the oncogenic and drug-
resistant RET mutants reproduce the experimental data and
provide a structural rationale of the drug inhibition profile,
which is consistent with the experimental data.FIGURE 8 (A) The average structure of the inactive
form of WT MET kinase with M1250 residue shown in
CPK model. (B) A closeup of structural packing near the
mutational site in the inactive WT MET kinase. (C) The
average structure of the inactive form of M1250T MET
kinase mutant with T1250 residue shown in CPK model.
(D) A closeup of structural packing near the mutational
site in the inactive T1250 MET kinase.
Modeling Kinase Cancer Mutation Effects 869FIGURE 9 The predicted binding mode of the ZD6474
inhibitor (in blue CPK model) with the WT RET Binding
site residues are shown in CPK models. (A) Superposition
of the predicted binding mode (in blue stick) with the crys-
tallographic conformation of the ZD6474 inhibitor from
the WT complex(default colors, stick model) in the WT
RET (B); V804G RET mutant (C); and V804M RET
mutant (D).Structural mapping of RET and MET cancer
mutations: modeling protein stability effects
Mapping of disease-linked mutations on the dynamical
profile of the WT RET and MET kinases has allowed
computational predictions of protein stability changes in
a number of important activating mutation sites. In the
CUPSAT approach (85), coarse-grained statistical poten-
tials, which are used to predict protein stability changes
caused by mutations, may primarily reflect the enthalpy
contribution to the free energy. Despite a rather simplistic
model, the CUPSAT-based protein stability assessment has
captured highly oncogenic RET and MET mutations as the
mutations which display a larger destabilization effect on
the inactive kinase structure (Figs. 11 A and 12 A). Another
approach for the protein stability analysis, FOLDx (87),
which provides an estimate of the differences in the empir-
ical folding free energy, has shown a similar trend in the
protein stabilities for both RET (Fig. 11 B) and MET mutants
(Fig. 12 B). Modeling protein stability effects using the MM-
GBSA approach (79,80) can arguably provide a more
detailed, quantitative evaluation of the thermostability and
complement the results obtained from knowledge-based,
empirical models. Importantly, all three approaches have re-
vealed a consistent trend and support a mechanism of activa-
tion, whereby the mutations that display the higher onco-
genic activity tend to have the greatest destabilization
effect on the inactive kinase structure.
Indeed, M918T RET and M12509T MET mutations, which
have the highest oncogenic activity, may result in the largest
destabilization effect on the inactive kinase structure (Figs.
11 and 12). Similarly, mutations of D1228 and M1250, which
cause a significant oncogenic transformation (61,97), are pre-
dicted to have a significant destabilization effect on the protein
structure. In contrast, the transforming potential of mutationsat H1094 and H1106 positions is known to be very small
(98). In accordance with these experimental data, we have
observed a small stabilization effect of H1094Y and
H1106D mutations on the autoinhibited MET structure. Inter-
estingly, M918T, Y806C, S891A, and A919V mutations,
which display a high transforming potential (62), have the
greater destabilization effect on the computed protein stability
changes (Fig. 11). Furthermore, P973L and M980T muta-
tions, which have markedly decreased the expression of the
RET protein with normal kinase activity and impair the
RET kinase activity (99), are shown to have a significant de-
stabilizing effect on the inactive form of RET kinase.
Although a detailed quantitative analysis and validation of
the computed protein stability changes would be warranted
only when the complete experimental data set becomes avail-
able, it is consistent with previous knowledge (100) and may
be instructive to note, in the context of this study, that the
effect of cancer mutations on normal kinase activity may be
associated with their impact on protein stability. Hence, the
results suggest that structural effects of activating cancer
mutations in RET and MET kinases may manifest in reduced
protein stability in the inactive state of the enzyme, thereby
triggering a detrimental imbalance in the dynamic equilib-
rium shifted toward the constitutively active kinase form.
Protein stability and structural effects of cancer
mutations: the energy landscape perspective
Our results suggest that structural topology of protein kinase
tends to preserve globally similar protein flexibility profiles
in the WT and mutational forms, whereas allowing for func-
tionally important local divergences near the mutational site.
This result is consistent with the recent studies, which have
revealed protein flexibility profiles that can diverge slowly,
being conserved both at family and superfamily levelsBiophysical Journal 96(3) 858–874
870 Dixit et al.FIGURE 10 The correlation between the computed and
experimental binding free energies of the ZD6474 inhibitor
with WT RET, M918T, V804G, and V804M RET mutants.(101,102). From an evolutionary point of view, structural
conservation of global protein flexibility and local deviations
at functionally critical regions for the mutants may be deter-
mined by natural selection of dynamical features that areBiophysical Journal 96(3) 858–874most important for function, as evolution may partly deter-
mine the functional motions for proteins. Thus, in case of
protein kinases, natural selection would tend to preserve
protein flexibility features that retain the ability of the proteinFIGURE 11 Structural mapping of cancer mutations and modeling protein stability effects in the RET kinase. Protein stability differences between the WT
RET and RET mutants using CUPSAT (A), FOLDx (B), and MM-GBSA (C). Mapping of cancer mutations into the structure of the RET kinase (D). Negative
values of protein stability changes correspond to destabilizing mutations. Mutational sites are in green CPK Ca models. Mutations with the largest destabi-
lization effect are shown in red.
Modeling Kinase Cancer Mutation Effects 871FIGURE 12 Structural mapping of cancer mutations and modeling protein stability effects in the MET kinase. Protein stability differences between the WT
RET and RET mutants using CUPSAT (A), FOLDx (B), and MM-GBSA (C). Mapping of cancer mutations into the structure of the RET kinase (D). Negative
values of protein stability changes correspond to destabilizing mutations. Mutational sites are in green CPK Ca models. Mutations with the largest destabi-
lization effect are shown in red.to fluctuate normally between active and inactive states. In
contrast, cancer kinase mutations may result in the increased
conformational space to be explored in the inactive state,
therefore disrupting optimal equilibrium balance between
active and inactive enzyme forms. The results of our study
can be interpreted from the perspective of the energy land-
scape theory (103–106), which suggests that less stable
and less selective protein states may be a result of a more
rugged bottom of the energy funnel, while functionally rele-
vant and specific protein structures are likely to be relatively
rigid, with a steep funnel of conformations leading to the
native state. In the framework of the energy landscape
theory, we can speculate that detrimental activating muta-
tions in protein kinases may act by shifting the accessible
conformational space away from regions that facilitate
normal functional performance of the kinase and perturb
the funneled nature of the free energy landscape. This anal-
ysis is consistent with a recently proposed mechanism (107),
in which proteins can modulate their function by altering the
accessible conformational space, while deleterious mutationsmay increase the probability of exploring additional confor-
mational regions that are incompatible with the normal func-
tional attributes. While the structural diversity of WT protein
kinases has been illuminated in recent years given the rapidly
increasing body of crystal structures, structural knowledge of
functionally important kinase mutants is limited and presents
an important challenge for structural pathology studies of
protein kinases (34). It is evident that the accuracy of compu-
tational structure predictions for kinase cancer mutants and
the atomic details of activation mechanisms can be fully
understood only when the respective high resolution crystal
structures become available. However, considering current
experimental challenges in dissecting the molecular basis
of cancer-causing mutations (34), the presented computa-
tional analysis provides useful insights into the mechanistic
basis of activating kinase mutations, which agree with avail-
able experimental data. Computational predictions from this
study can inform future experiments exploring the molecular
pathology of tumorigenesis and facilitate rationale drug
design of personalized cancer therapies.Biophysical Journal 96(3) 858–874
872 Dixit et al.CONCLUSIONS
Computer simulations of the conserved cancer mutations in
the RET and MET kinases have allowed us to elucidate at
atomic resolution the impact of these mutations in altering
protein kinase structure, dynamics, and stability. The func-
tional role of a structurally conserved mutational hotspot in
the RET and MET kinases, shared by M918T RET and
M1250T MET, has been deciphered by simulating the differ-
ential effect of these mutations on active and inactive kinase
states. We have found that the mechanistic basis of the acti-
vating RET and MET cancer mutations may be driven by
an appreciable free energy destabilization of the inactive
kinase state in the mutational forms. The computed protein
stability differences between the WT and cancer mutants
are consistent with circular dichroism spectroscopy and
differential scanning calorimetry experiments, and therefore
provide a molecular rationale of the observed phenomenon.
These results support the molecular mechanism of activation,
which causes a detrimental imbalance in the dynamic equilib-
rium shifted toward the active form of the enzyme. Further-
more, structural mapping of cancer mutations in RET and
MET kinases and the computed protein stability changes
using three different approaches have revealed a consistent
trend and reinforced the proposed mechanism of activation,
whereby the mutations that display the higher oncogenic
activity tend to have the greatest destabilization effect on
the inactive kinase structure. Ultimately, understanding struc-
tural and functional effects of conserved cancer mutations can
aid in the development of therapeutics to specifically combat
mutation-dependent tumorigenesis, while avoiding potential
side effects related to normal functions of the targeted kinase.
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